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Purpose: To evaluate lymphatic system targeting and inhibitory ability of N15P nano-liposomal 
preparation (naLipo-N15P) of CXCR4 receptor antagonist in HIV infection.  
Methods: Chemotactic and chemotaxic inhibition activity assays were used to analyze the biological 
activity of naLipo-N15P. The anti-HIV potential of NaLipo-N15P in vitro was evaluated when NaLipo-
N15P combined with the peripheral blood mononuclear cells of Macaca fascicularis which carry the 
Simian immunodeficiency virus. Furthermore, the anti-HIV potential in vivo of NaLipo-N15P was 
evaluated by the plasma concentration and tissue distribution (Ki) 
Results: The half-maximal inhibitory concentration of naLipo-N15P binding to CXCR4 as an antagonist 
in competition with SDF-1α was 1.89 pM while Ki was 2.4 pM. Viral load was 289 ± 45. NaLipo- N15P 
majorly accumulated in liver and spleen.  
Conclusion: When N15P is encapsulated into nano-liposomes, it not only retains specific binding to 
CXCR4 and facilitates cell-type-specific targeting of nano-liposomes to PBMCs with high CXCR4 
expression, but also shows enhanced anti-HIV effect. Therefore, we propose that naLipo-N15P as a 
CXCR4 antagonist will play an important role in inflammation and blocking of HIV infection. 
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Chemokines are a family of small (8 – 10 kDa) 
proteins that act as chemoattractants by 
signaling through their receptors and activating 
target cells. CXCR4 is a G-coupled heptahelical 
receptor that first drew attention as a major 
coreceptor for the entry of HIV(human 
immunodeficiency virus)[1]. The CXCR4 and its 
only characterized chemokine ligand, stromal 
cell-derived factor-1 (SDF-1), are important in 
HIV infection [2]. A variety of compounds that 
target CXCR4 to prevent HIV infection have been 
developed [2]. Viral macrophage inflammatory 
protein (vMIP)-II, a chemokine encoded by 
human herpes virus 8, displays diverse 
interactions with both CC and CXC chemokine 
receptors and inhibits HIV-1 entry mediated 
through CCR3, CCR5, and CXCR4 [3]. 
Comparison of the amino acid sequences of 
vMIP-II and other human chemokines reveals 
that the N-terminus of vMIP-II has little homology 
with either CC or CXC chemokines, whereas the 
other regions of vMIP-II share a high sequence 
similarity with CC chemokines such as MIP-1α 
and MIP-1β [4]. Thus, it is conceivable that the 
unique N-terminal sequence of vMIP-II may 
confer a biological function.  
 
Zhou et al [5] found that the N-terminus of vMIP-
II is essential for its function via CXCR4. In 
contrast to the full-length protein, a peptide 
corresponding to residues 1–21 derived from the 
N-terminus of vMIP-II was shown to bind strongly 
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to CXCR4. However, the spatial conformation of 
residues 1–21 of vMIP-II is extremely variable 
due to its poor stability, leading to variations in its 
biological activity. Nevertheless, a multiple 
sequence alignment between vMIP-II and the 
CXCR4 receptor-binding factor showed that the 
N-terminal 1-15 peptide has the same specific 
binding to CXCR4. Furthermore, the N-terminal 
1–15 peptide of vMIP-II was more stable (the 
instability index (II) was 28.79, the residues 1–21 
of vMIP-II was 57.29). To test this hypothesis, a 
synthetic peptide derived from the N-terminus 1–
15 of vMIP-II was synthesized 
(LGASWHRPDKCCLGY, designated as N15P).  
 
At present, nanotechnology plays an important 
role in the development of new types of 
therapeutic interventions [6]. Systemically 
administered nano-therapeutics have been 
shown to enhance the therapeutic index of drugs, 
either by increasing the drug concentration at the 
site of interest and/or by decreasing exposure in 
healthy tissues. Therefore, in order to improve 
the antagonistic activity of N15P against CXCR4 
and to target prevention of HIV infection in 
inflammatory tissue with high CXCR4 expression 
in vivo, the peptideas encapsulated into nano-






Human PBMCs were separated from whole 
blood by centrifugation using Ficoll density 
gradient centrifugation. Lymphocyte separation 
medium was purchased from Sigma (USA). The 
recombinant human chemokine SDF-1a was 
lyophilized and dissolved as 1 or 2.5 μg/μL stock 
solutions in sterile phosphate-buffered saline 
(PBS) and stored at -20 °C in aliquots. Na125I 
was purchased from R&D Systems Inc. Cell 
culture media plus 10% fetal bovine serum were 
also purchased from R&D Systems Inc (USA). 
The γ- radioimmunoassay counter and RPMI 
1640 containing 0.5% fetal bovine serum was 
purchased from Sigma. Macaca fascicularis 
bearing simian immunodeficiency virus (SIV) 
were obtained from our laboratory (We have 
acquired approval from the JinNan University 
Ethical Committee in accordance with "Principles 
of Laboratory Animal Care". The peptide (NH2-
LGASW HRPDKCCLG Y -COOH, named N15P) 
was synthesized by Ji Nuo Tai Biological 
Technology Co., Ltd. Xian, China), using 
standard fluorenylmethyloxycarbonyl chemistry 
and purified by high-performance liquid 
chromatography, sequence confirmation was by 
mass spectroscopy; the purity was 98%, and the 
molecular weight was 1705.9. 
Radioiodination  
 
The N15P was radioiodinated with Na125I using 
the chloramine T method and acetylated using 
acetic anhydride [7]. The labeling rate and 
radiochemical purity were 80 ± 5.12 and 89.00 ± 
3.67 %, respectively. The specific activity was 
1142 μCi/nM,  
 
Preparation of naLipo-N15P  
 
The nano liposomes were prepared using the 
reverse rotary evaporator combined with 
ultrasound. Lecithin and cholesterol (ratio, 5:1)  
were dissovled in diethyl ether in a centrifuge 
tube by vortexing in a WH-2 miniature vortex, 
then transferred to a round bottom rotating flask. 
While stirring the mixture of lecithin cholesterol 
and diethyl ether, N15P was added to the 
mixture. The round bottom rotating flask was 
placed in a water bath (temperature, 45 °C) to 
completely volatilize the ether .The pale yellow 
layer in the bottom of the rotating round-
bottomed flask was dissolved with 10 ml diethyl 
ether again, and 10 ml double -distilled water 
was added . The mixed liquid was poured into a 
beaker for ultrasonic vibration for 5 minutes. The 
sonicated liquid mixture was poured into a round 
bottom flask for rotary evaporation for 35 min. 
The liquid mixture converted into a milky white 
powder, named nano-liposome. The results of 
particle size analysis and potential detection of 
the nano liposome showed that its shape is 
circular, and evenly distributed; the average 
particle diameter was 80.3 ± 11.37 nm; zeta 
potential was 29.37 ± 3.30 mV, and they 
remained fairly stable after storage in a 
refrigerator for 1 month. After 4 months of 
storage at -20 °C, the encapsulation efficiency 
was still 56.73±0.22. The encapsulation 
efficiency of naLipo-N15P at -20 °C was higher 
and more stable than at either 4 °Ç or 25 °C 
(46.65 ± 0.19 and 20.52 ± 0.17 respectively).  
 
Chemotactic activity assay  
 
MTT assay is sensitive for the detection of the 
cytotoxicity of N15P for peripheral blood 
mononuclear ells (PBMCs), and thus the method 
can assess drug toxicity in normalhuman cells, 
provide a measure of chemotaxis. MTT assay 
was used to determine the chemotactic activity of 
healthy human PBMCs treated with naLipo-
N15Ps and by N15P. Different concentrations of 
naLipo-N15P and N15P (10× dilutions from 1000 
ng mL-1 to 0.1 ng mL-1 with RPMI 1640) were 
added to PBMCs (1×106 cells mL-1). RPMI 1640 
without serum solution was used as the blank 
control; the same amount of SDF-1α was used 
as the positive control. The absorbance of each 
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well at 490 nm was measured using a microplate 
reader (DNM-9606, ShangHai BILON). The 
resulting cell viability was calculated as 
described previously [8]. 
 
Chemotactic inhibition activity assay  
 
To detect the chemotactic inhibition activity of 
naLipo-N15P, we tested nine different 
physiological chemokine receptors on PBMCs 
(IL-8, MIP-3α, MIP-3β, MCP-1, exotaxin-2, IP-10, 
I-309, SDF-1α, purchased from Sigma). RPMI 
1640 was the blank control, 10 ng/mL SDF-1α in 
RPMI 1640 as the positive control, and different 
concentrations of naLipo-N15P and N15P (0.1, 1, 
10, 100, and 1000 ng/ml) in chemotactic buffer 
as the experimental group. Chemotaxis 
experiments were conducted in a 24-well 
Transwell unit, incubated for 2 h at 37 °C in 5% 
CO2. Cell density was counted using a 
hemocytometer, and the data analyzed using 
SPSS Statistics software, version17.0.  
 
Competitive binding to CXCR4  
 
In order to study receptor-ligand binding, 
competitive binding experiments were performed 
using a single concentration (0.5 nM) of 125I- 
N15P and 125I- naLipo-N15P in the presence of 
increasing concentrations of unlabeled ligand in 
a 100-μL final volume of binding buffer (50 nM 
Hepes, pH 7.4, 1 nM CaCl2, 5 nM MgCl2, 0.1 % 
bovine serum albumin) containing 1 × 106 
PBMCs. Nonspecific binding was determined by 
the addition of 100 nM unlabeled naLipo-N15P or 
N15P, respectively. Samples were incubated for 
60 min at room temperature. The incubation was 
terminated by separating the cells from the 
binding buffer by centrifugation and washing 
once with 500 μL cold binding buffer. Bound 
ligand was quantified by counting γ emissions. 
 
In ligand competition experiments, the 
concentration of 125I-N15P or 125I- naLipo-N15P 
and 125I-SDF-1a were fixed at 0.5 nmol/L, and 
unlabeled N15P or naLipo-N15P were added to 
the PBMC suspension. Samples were incubated 
for 60 min at room temperature. The incubation 
was terminated by separating the cells from the 
binding buffer by centrifugation and washing 
once with 500 μL of cold binding buffer. Samples 
were washed with PBS two times by 
centrifugation at 3000 ×g for 3 min to wash away 
free 125I-N15P , 125I-naLipo-N15P and 125I-SDF-
1a. Bound ligand was quantified by counting γ 
emissions. 
     
Detection of specific binding: The 
experimental group was treated with 200 ng/mL 
naLipo-N15P and N15P. SDF-1α was used as 
the positive control group and human serum 
albumin as negative control group. The cells 
were then treated with 100 ng/mL CXCR4-FITC-
monoclonal fluorescent antibody, after incubated 
for 2h. The coverslip and slide were sealed with 
a solution of glycerol and PBS. The values were 
determined by laser scanning confocal 
microscopy (LSCM) with absorbance/emission 
wavelengths of 480/550 nm. 
 
Pharmacokinetic properties of naLipo-N15P  
 
Equal amounts of naLipo-N15P (1 mg/kg) or 
N15P were injected into the tail vein of Macaca 
fascicularis infected with SIV. The blood was 
collected at various time points (15, 30, 45, 60, 
75, 90, 120, 150, 180, 240, and 300 min) to 
detect the plasma concentration. Ninety minutes 
after the injection of naLipo-N15P, or 75 min after 
the injection of N15P, the heart, kidney, spleen, 
lung, and liver were removed, and the associated 
adipose tissue and connective tissue were 
cleaned. After washing with PBS, the surface 
water was drained using filter paper. The right 
amount of tissue was weighed, and an equal 
volume of saline was added, followed by high-
speed homogenization. The homogenate was 
centrifuged at 2000× g for 15 min and sterilized 
by passing through a microporous membrane 
(0.22 μm). The supernatant was placed in a 4°C 
refrigerator to be used for tissue distribution 
studies. 
 
Effect of naLipo-N15P on SIV infection  
 
The blood of Macaca fascicular infected with SIV 
was extracted, and the PBMCs separated. The 
same amount of naLipo-N15P (1 mg/kg) and 
N15P was incubated with these PBMCs at 25 °C 
in 5 % CO2, for 24 h. PBMCs without naLipo-
N15P or N15P were used as a negative control, 
and equal amounts of T20 as anti-HIV drugs 
were added for the positive control. Each group 
was detected by flow cytometry after 24 h 
incubation. Viral load was detected by real-time 
polymerase chain reaction (PCR) after 24 h 
incubation. The conserved gag and env region 
was amplified using specially designed primers 
(forward primer: 5'-AGTGGGGGGAC 
ATCAGCAGCCATGCAAAT-3', reverse primer: 
5'- GCTATGTCAGTTCCC CTTGGTTCTC-3'; 
primers synthesized by Shanghai Biological 
Engineering Co. Ltd.), to establish a system for 
the determination of the viral load of SIV by real-
time PCR in each of the following groups: 
naLipo-N15P-treated, N15P-treated, untreated 
(blank), and T-20-treated (positive control, a kind 
of HIV drugs, presented by Nan Yang Central 
Hospital) .  
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Statistical analysis   
 
All of the data were analyzed using SPSS 
software, version 17.0. Significant level was set 




The results of particle size and zeta potential 
analyses of the nano-liposome showed that 
particles were circular, and evenly distributed; 
the mean particle diameter was 80.3 ± 11.37 nm 
and zeta potential was 29.37 ± 3.30 mV; they 
remained fairly stable after storage in a 
refrigerator for 1 month. After 4 months of 
storage at -20 °C, the encapsulation efficiency 
remained 56.73±0.22. The encapsulation 
efficiency of naLipo-N15P at -20 °C was higher 
and more stable than at 4 and 25 °C (46.65 ± 
0.19 and 20.52 ± 0.17, respectively).  
 
No chemotactic effect on PBMCs SDF-1α is the 
only known chemokine that binds to and 
activates CXCR4. Therefore, we used SDF-1α 
stimulation of PBMCs as a positive control. The 
number of migrating cells in the experimental 
group was divided by the number of migrating 
cells in the blank control group to calculate the 
chemotactic index. Compared with control wells, 
the absorbance values from wells treated with 
different concentrations of naLipo-N15P were not 
significantly different (p > 0.05). Therefore, 
naLipo-N15P had little impact on the survival and 
growth of normal PBMCs. Additionally, different 
concentrations of naLipo-N15Ps show apparently 
no toxic effect on PBMCs. 
 
Inhibition of chemotactic activity induced by 
SDF-1α  
 
The effects of different concentrations of naLipo-
N15P (0.1, 1, 10, 100 and 1000 ng/mL) on 
PBMC activity were analyzed by one-way 
analysis of variance. The differences among the 
various groups were statistically significant (p = 
0.001 < 0.05, a = 0.05), but there was no 
difference between the chemotactic index values 
of each experimental group and that of the blank 
control group.  
 
We calculated the chemotactic index for each of 
the tested groups; the chemotactic index for the 
positive control group was 5.86 ± 1.15, whereas 
the chemotactic indices of the experimental 
groups were < 2. From the statistical point of 
view, a chemotactic index < 2 denotes the 
absence of chemotaxis. This result indicated that 
PBMCs treated with N15P and naLipo-N15P 
showed no chemotaxis.  
 
The research about the chemotaxic index 
induced by IL-8, IP-10, I-309, MCP-1, SDF-1α, 
eotaxin-2, MIP-3α, and MIP-3β indicated that, the 
naLipo-N15P and N15P inhibited the chemotactic 
activity induced by SDF-1α in a dose-dependent 
manner, but there was no obvious effect on the 
chemotactic activities induced by the other seven 
kinds of chemokines. The number of PBMCs 
exhibiting chemotactic activity induced by SDF-
1α obviously reduced upon treatment with the 


























Figure 1 The chemotaxic index induced by IL-8, IP-10, 
I-309, MCP-1, SDF-1α, eotaxin-2, MIP-3α, and MIP-3β 
 
When the concentration of naLipo-N15P and 
N15P were 0.1 ng/mL, the cell chemotaxis 
induced by SDF-1α was inhibited. The inhibition 
rate reached 78.88% when the concentration of 
naLipo-N15P and N15P were 1000ng/ml. What’s 
more, the chemotactic index of PBMCs treated 
with different concentrations of naLipo-N15P and 
N15P (0, 0.1,1,10,100 and 1000 ng/ml), 
compared with the control cells, shown that there 
was no significant differences between the 
inhibition of SDF-1α-induced chemotactic activity 
by naLipo-N15P and N15P (p > 0.05). By the 
Reed-Murch method, the half maximal inhibitory 
concentration (IC50) of naLipo-N15P, which plays 
a role in the chemotactic activities induced by 
SDF-1α, was calculated as 3.31 pg/mL. The 
results show that naLipo-N15P can influence the 
chemotactic activity induced by SDF-1α in 
PBMCs in an apparently dose-dependent 
manner. 
 
Competitive binding of naLipo-N15P to 
CXCR4  
 
We used flow cytometry to detect the biological 
activity of naLipo-N15P with the chloramine T 
method as previously described [9]. Bound 
radioactivity was measured using a Wallace 
counter (Turku, Finland) with 70% efficiency. 
Specific binding (Bs) was determined by 
subtracting nonspecific binding (BNS) from total 
binding (BT), and the free ligand concentration 
was estimated by subtracting the amount of 
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bound ligand from the total amount of ligand 
added. The equilibrium Kd was calculated as the 
free concentration of radioligand at half-maximal 
binding, by fitting data to the Hill equation and by 
linear Scatchard transformation [10].  
 
The data were evaluated by a nonlinear four-
parameter logistic model to estimate the IC50 
value (the concentration of competitor at half-
maximal specific binding). The relative binding 
affinity (RBA) of each competitor was calculated 
as the ratio of the concentrations of N15P or 
naLipo-N15P and competitor required to reduce 
specific radioligand binding by 50 % (ratio of IC50 
values). The RBA values of N15P and naLipo-
N15P were arbitrarily set at 100. The Cheng-
Prusoff equation was used to calculate the Ki of 
the various competitors. The IC50 can be 
calculated from the competitive inhibition curve of 
naLipo-N15P as a CXCR4 antagonist (fig 2-3). 
The IC50 was 5.01 pM, indicating increased 
competitive inhibition of CXCR4 binding 
compared to that seen with N15P alone. The 
competitive binding to SDF-1α was 1.89 pM and 
the Ki was 2.4 pM. The Kd values calculated from 
the saturation curves were 1.11 ± 0.21 nmol/L for 
PBMCs, and 14.06 ± 0.89 nmol/L for SDF-1α. 
The Bmax was 611.1±0.58 fmol/mg. The results of 
a saturation ligand binding assay with125I-naLipo-
N15P show that naLipo-N15P bind with high 
affinity to membrane receptors on human 
PBMCs. Further, 125I-naLipo -N15P strongly 
competed with the CXCR4 binding of 125I-SDF-1α 
in a concentration dependent manner. These 
results indicate that the inhibition of CXCR4 
binding to SDF-1α by naLipo-N15P is as high as 
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Figure 2: The binding of naLipo-N15P/N15P to the 
CXCR4 receptor on human PBMCs (Scatchard plot）  
 
Specific binding to CXCR4 on the surface of 
PBMCs  
 
Data from the negative and positive control 
groups indicate the reliability and credibility of 
this experiment. CXCR4 molecules, labeled with 
FITC monoclonal antibodies, exhibited green 
fluorescence on the cell surface when viewed 
under laser scanning confocal microscopy, 
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Figure 3: The competitive inhibition curve of naLipo-
N15P for CXCR4 binding as measured by a saturation 
ligand binding assay with125I-N15 (Logit plot).  
 
surface. The negative control group (human 
serum albumin) and the blank control group 
exhibited linear green fluorescence around the 
cells, with little fluorescence inside the cell. In the 
SDF-1a-treated positive control group, CXCR4 
was distributed at the cell surface, the linear 
green fluorescence around the cells was 
reduced, and the intracellular green fluorescence 
was higher. The naLipo-N15P experimental 
group exhibited decreased linear green 
fluorescence around the cells, and increased 
intracellular green fluorescence. These data 
indicate that the cell surface receptor CXCR4 
was partially internalized into the cells upon SDF-
1a stimulation (Fig. 4). Based on flow cytometry 
and laser confocal detection of receptor 
internalization, naLipo-N15Ps, in contrast to 
N15P, not only induce CXCR4 internalization, but 
also prevent internalized receptors from cycling 




       a                 b                  c                 d 
Figure 4: Confocal microscopic images: untreated 
PBMCs (blank control, a), human serum albumin-
treated PBMCs (negative control, b), fractalkine-
treated PBMCs (positive control, c), and PBMCs 
treated with naLipo-N15P (experimental group, d) 
 
Targeted distribution of naLipo-N15Ps in vivo  
 
NaLipo-N15Ps were present at maximal 
concentrations in blood at 96.75 min, and the 
concentration was maintained at relatively higher 
levels for a relatively long period than N15P. The 
plasma concentration-time curve of naLipo-
N15Ps indicated that the area under the curve 
(AUC) of naLipo-N15P (6383.17 ng·ml-1·min) 
was higher than that of N15P (2272.53 ng·ml-
1·min). The distribution phase half-life of naLipo-
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N15P was 46.53 min, and the elimination phase 
half-life was 97.30 min. The distribution phase 
half-life of N15P was 49.86 min, and the 
elimination phase half-life was 41.99 min. The 
speeds of naLipo-N15P and N15P distribution 
from the central compartment to the peripheral 
compartment were similar, whereas the 
difference in elimination speeds was significant. 
NaLipo-N15Ps accumulated in target tissues, 
such as the heart, spleen, kidney, liver, lung, and 
other tissues, particularly in the liver and spleen, 
and decreased rapidly with time. This 
observation also indicates that liposome 
encapsulated drugs have a greater half-life in the 
circulation, facilitating HIV-targeted drug delivery. 
By tissue distribution, we found that the drug 
concentration in the liver rose from 13.26 ± 1.37 
to 61.41 ± 1.58 ng/ml, whereas that in the spleen 
rose from 2.97 ± 0.11 to 20.71 ± 0.32 ng/ml. The 
concentration of naLipo-N15P also increased in 
lung tissue.  
                                                   
Blocking the effect on SIV infection of PBMCs  
 
Following DNA amplification by real-time PCR, 
the data were analyzed by the system software. 
A standard curve was generated, with the 
logarithm of the starting template concentration 
plotted on the x-axis, and Ct on the y-axis. The 
regression equation for the standard curve was y 
= -2.321x + 26.752, with an R2 value of 0.9981. 
The standard curve showed a good linear 
relationship within the range of 101 ~ 104 copies. 
The SIV viral loads in PBMC culture 
supernatants from the different experimental 
groups were calculated and expressed as the 
copy number per milliliter of cell culture 
supernatant. The actual viral load of the sample 
was calculated as the detected viral content 
divided by 0.9. The Ct of each sample was 
detected by real-time PCR, and the viral load 
was calculated from the standard curve based on 
the regression equation. The viral load of the 
positive control group was 8924 ± 1036, while 
the naLipo-N15P-treated group was 289 ± 45, 
the N15P-treated group was 665 ± 81, and the T-
20-treated group was 274 ± 34. There were 
significant differences between the viral loads of 
the two treatment groups and the positive control 
group; however, no significant differences were 
seen between the naLipo-N15P-treated and T-
20-treated groups. These data demonstrate that 




The process of chemokines binding to receptor is 
as follows. Chemokine moves to the the sites of 
corresponding receptor. The exposed N-terminus 
combines with the N-terminus of the receptor to 
modify it to a minor groove, thus causing overall 
the chemokine receptor, to become allosteric, 
and expose the membrane binding site hidden in 
the transmembrane helix of membrane. The 
biological effect is exerted after the signal is 
generated and transmitted into the cells. Studies 
show that although the chemokines that change 
or truncate the N-terminus lose inflammatory 
ability, they can still combine with receptor. Thus 
they become the corresponding receptor 
antagonist. Thus, it seems that N-terminal 
contains a chemokine binding site, thus 
suggesting that chemokines binding receptor 
sites constitute a target for drug to bind 
selectively. 
 
Because vMIP-II can combine with CCR1, 
CCR3, CCR5 and CXCR4 and other chemokine 
receptors , and does not cause receptor 
activation, so we predicted vMIP-II can be used 
as a blocking agent of these receptors. Therefore 
vMIP-Ⅱcan effectively prevent the virus from 
infecting target cells, by blocking co-receptor 
CCR5/CXCR4, which undoubtedly provides 
excellent molecular shape for exploring the 
design of chemokine receptor antagonist and 
provided better research to design small 
molecule anti-HIV drugs by the interaction study 
of chemokine ligand - receptor. 
 
In the present work, we used a synthetic peptide 
approach to study the role of the N-terminus of 
vMIP-II in the recognition and binding of the 
important chemokine receptor CXCR4. A high 
positive charge is seen in several peptide and 
non-peptide inhibitors of CXCR4, such as T20, 
ALX40-4C, and AMD3100 [11]. However, the 
utility of these molecules is limited due to poor 
stability, toxicity, poor targeting in vivo, and other 
reasons. 
In order to improve targeting and stability, 
enhance the bioavailability of N15P, N15P was 
encapsulated into liposome. We studied the 
biological activities of naLipo-N15P by 
chemotaxis research, reporter binding activities 
and tissue distribution research, to measure it as 
CXCR4 receptor antagonist.  
 
Nanoliposomes (small unilamellar vesicles, 
SUV), is one of the more desirable liposomal 
pharmaceutical carrier. The specific advantages 
of stability, absorbability distribution, etc, are why 
nanoliposomes are employed to encapsulate 
hydrophilic, hydrophobic and amphiphilic drugs. 
Sustained-release drugs can play a 
pharmacodynamic role when they are delivered 
to target cells. Hence N15P was encapsulated in 
liposomes to change the distribution of drug in 
vivo, improve therapeutic index, as well as 
reduce therapeutic dose and drug toxicity. 
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Encapsulated drugs are mainly concentrated in 
the liver, spleen, lungs and other organs which 




Our study demonstrates that a peptide 
comprising the first 15 residues of the N-terminus 
of vMIP-II, encapsulated into liposomes, did not 
cause chemotaxis in normal human lymphocytes, 
but could inhibit the chemotaxis of PBMCs 
caused by a physiological chemokine. Such a 
peptide encapsulated into nano-liposome could 
potentially serve as a delivery system for drugs 
against HIV or inflammatory diseases related to 
CXCR4 to increase their therapeutic index. We 
believe that naLipo-N15P, acting as a CXCR4 
antagonist, readily accesses sites of high CXCR4 
expression. Moreover, naLipo-N15Ps play a 
biological role by specifically and competitively 
blocking SDF-1 binding to CXCR4. We envision, 
therefore, that the CXCR4 inhibitory effect of 
naLipo-N15P can be exploited in the treatment of 
advanced AIDS, cancer metastasis, severe 
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